NEW POSITIONING
1 Glenmark's focus on creating a global presence in the respiratory segment suggests a strategic shift towards specialised therapeutic areas
2 Its renewed focus on complex generics and speciality products aligns with industry trends towards higher-margin products
3 Gaining market share in India and expanding into Europe and RoW markets indicates a focus on geographic diversification and growth opportunities
4 Monetising the innovation portfolio through licensing deals reflects a strategy to leverage intellectual property for additional revenue streams
5 Sharper focus on free cash generation underscores financial discipline and liquidity management priorities
MUMBAI’S AFTERNOON SUN has bathed Glenmark House in Andheri East in a warm glow as Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals Ltd, strides into a boardroom for an interview. Saldanha, who has led Glenmark for nearly 30 years, the last 12 as CMD, has had enough of the volatile business of making APIs or active pharmaceutical ingredients, taking debt for working capital and depending on best-selling brands with margins measured in teaspoons.
Debt is now a bad word in Glenmark House. Saldanha’s buzzwords now are complex generics and speciality drugs (read: fat margins). Glenmark jettisoned its ₹4,600-crore debt in the second quarter of 2024 by selling a 75% stake in its API business to Nirma Ltd on September 21, 2023, for around ₹5,651 crore. It aims to be debt-free by 2026.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
BIG SHOTS
GIVEN THAT MORE THAN 40% OF INDIAN ADULTS ARE STRUGGLING WITH OBESITY AND DIABETES, AFFORDABLE WEIGHT-LOSS DRUGS ARE EXPECTED TO SIGNIFICANTLY DISRUPT THE PHARMACEUTICAL LANDSCAPE IN THE COUNTRY THIS YEAR. AND, THE WEIGHT MANAGEMENT MARKET COULD REACH ₹3.99 LAKH CRORE BY 2032, GROWING AT A CAGR OF MORE THAN 9%
THE END OF AMERICAN FINANCIAL EXCEPTIONALISM
As the dollar cycle reverses and Asia's rise continues, Indian growth will accelerate
HOW TO ADAPT TO EXTREME HEAT
India is vulnerable to extreme heat and yet unprepared. But various initiatives provide a glimpse of what is possible when collaboration and ingenuity come together
THE WORLD IN 2030
The policy implications are that India would have to maintain a strong link to a re-industrialising US but find a way to use Chinese capital and inputs
A PEEK INTO THE FUTURE
INDIA IN 2025 AND BEYOND: TRENDS TO WATCH OUT FOR
"STEERING SBI INTO THE FUTURE"
C.S. Setty, Chairman of the State Bank of India, talks about his plans for the bank, the strategy for the future, and technology, among other things
"Outlook for India is very positive"
Paul Uren, Head of Investment Banking (Asia-Pacific), J. P. Morgan, on M&A activity, the environment of investment banking market in India, and more
The 2025 Slate
The Indian film industry is hoping that 2025 will mark the return of big-budget blockbusters
TECH, SET, GO!
With up to 30 tech start-ups looking to go public, the year promises to be a turning point for India's thriving start-up ecosystem
CAUTION AHEAD
A series of events in the first few weeks of the New Year could shape the trajectory of the equity markets, especially the Trump administration's policies
